

In the Claims

Please cancel claims 30-32, 34, and 38, without prejudice.

Claims 1-23 (canceled)

24. (previously added) A pharmaceutical composition, comprising:

- (a) at least one polynucleotide, wherein the polynucleotide comprises a sequence of a binding site for a transcription factor and which is selected from the group consisting of GATTGCCTGACGTCAGAGAG (SEQ ID NO:8),
GGAATGACGTTCCCTGTG (SEQ ID NO:9),
AGCTATGACGTTCCAAGG (SEQ ID NO:10),
GCTTGATGACTCAGCCGGA (SEQ ID NO:11),
TCGATCGGGGCGGGGCGAGC (SEQ ID NO:12),
TGCAGATTGCGCAATCTGCA (SEQ ID NO:13),
AGCGGGGGCGAGCGGGGGCG (SEQ ID NO:14),
GTCCATTTCCTGTAATCTT (SEQ ID NO:16),
TATGCATATTCCTGTAAGTG (SEQ ID NO:17),
CTGATTTCCTCGAAATGATG (SEQ ID NO:19),
AGATTCTAGGAATTCAATC (SEQ ID NO:20),
GTATTTCCTCAGAAAAGGAAC (SEQ ID NO:21),
AAGCGAAAATGAAATTGACT (SEQ ID NO:22), and
CAGGCATAACGGTTCCTAG (SEQ ID NO:23); and
(b) a pharmaceutically acceptable carrier and/or diluent.

25. (previously added) The pharmaceutical composition according to claim 24 further comprising at least one antigen.

26. (previously added) The pharmaceutical composition according to claim 24 characterized in that the polynucleotide comprises at least one phosphorothioate linkage.

27. (previously added) The pharmaceutical composition according to claim 25, wherein the antigen is selected from the group consisting of peptides, polypeptides, proteins, polysaccharides, steroids, tumor cell antigens, and tumor cells.

28. (previously added) The pharmaceutical composition according to claim 24, wherein the binding site for a transcription factor is a binding site for a transcription factor of a cytokine.

29. (previously added) The pharmaceutical composition according to claim 28, wherein the sequence is selected from the group consisting of SEQ ID NO:9 and SEQ ID NO:10.

Claims 30-39 (canceled)